UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q/A

(Amendment No. 1)AMENDMENT NO. 1

(Mark One)

For the quarterly period ended March 31, 2018June 30, 2022

ORor

For the transition period from                     to 

Commission File Number: 001-37718

Spring Bank Pharmaceuticals, Inc.F-STAR THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Registrant’s telephone number, including area code: (508) 473-5993+44-1223-497400

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrantRegistrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrantRegistrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒    No   NO ☐

Indicate by check mark whether the registrantRegistrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantRegistrant was required to submit and post such files). Yes☒    No   NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B)13(a) of the SecuritiesExchange Act. ☒☐

Indicate by check mark whether the registrantRegistrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  YES ☐    No   NO ☒

AsThe number of April 27, 2018, the registrant had 13,168,588 shares of common stock, $0.0001 par value per share, outstanding.Registrant’s Common Stock outstanding as of June 30, 2022 was 21,584,723.

Explanatory Note

EXPLANATORY NOTE

This

F-star Therapeutics, Inc. (“F-star”, “our” or “we”) is filing this Amendment No. 1 to the Quarterly Report on Form 10-Q/A (this “Amendment”) amends theto its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2018June 30, 2022 (the “Original Report”Form 10-Q”), which was filed by Spring Bank Pharmaceuticals, Inc. with the Securities and Exchange Commission on April 27, 2018.August 11, 2022. This Amendment is being filed solely to re-file Exhibits 31.1replaces in its entirety Part I, Item 4 “Controls and 31.2 to include a portion of the text required in paragraph 4 of the Section 302 certifications included under Procedures” (“Item 6 of Part II4”) of the Original Report.Form 10-Q, which inadvertently did not include the conclusion by our Chief Executive Officer and Chief Financial Officer of the effectiveness of our disclosure controls and procedures, as required by Item 307 of Regulation S-K.

The complete text of Item 4, including the revised language referenced above, is provided below.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of June 30, 2022, our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the Original Report. Accordingly, this Amendment shouldeffectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act to ensure that information required to be readdisclosed by the Company in conjunction with the Original Report, which continuesreports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC rules and forms, and that such information is accumulated and communicated to speakour management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that such disclosure controls and procedures were effective as of June 30, 2022.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the datecost-benefit relationship of possible controls and procedures.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Original Report.Exchange Act) during the three months ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

1

PART II. OTHER INFORMATION

Item 6. Exhibits

EXHIBIT INDEX

2

SIGNATURES

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

3